Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Patent number: 11116830
    Abstract: Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a Neisseria meningitidis capsular polysaccharide. The carrier protein includes an N. meningitidis factor H binding protein (fHbp) linked to cholera toxin subunit B (CTB). Administration of the immunogenic compositions elicits an immune response that includes production of meningococcal polysaccharide-specific and fHbp-specific antibodies. Use of the immunogenic compositions as meningococcal vaccines is also described.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 14, 2021
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gregory A. Price, Che-Hung Robert Lee, Margaret C. Bash
  • Patent number: 11110089
    Abstract: There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein W, X, Y, Z, R1, R2 and R3 have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Elias Set Jenö Arnér
    Inventors: Elias Set Jenö Arnér, William Chester Stafford, Nathan Patrick Coussens, Diane Karen Luci, David Joseph Maloney, Anton Simeonov, Ajit Jadhav, Thomas S. Dexheimer
  • Patent number: 11110150
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 7, 2021
    Assignees: NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
  • Patent number: 11111478
    Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: September 7, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
  • Patent number: 11110181
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 7, 2021
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • Patent number: 11111306
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • Patent number: 11112472
    Abstract: A gradient system characterization function (e.g., a gradient system transfer function) may be developed by measuring a behavior of the MR device at a target temperature and developing at least one gradient system characterization function for a gradient coil of a magnetic resonance (MR) device at the target temperature based on the measured behavior. A patient may be subsequently imaged by the MR device, wherein the imaging process comprises measuring a temperature of a gradient coil, determining a gradient system characterization function at the measured temperature, calculating a pre-emphasized gradient of the gradient coil, and imaging the patient using the pre-emphasized magnetic field component.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: September 7, 2021
    Assignees: Siemens Healthcare GmbH, Julius-Maximilians-Universität Würzburg, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gudrun Ruyters, Andrew Dewdney, Manuel Stich, Herbert Köstler, Christiane Pfaff, Tobias Wech, Adrienne Campbell
  • Patent number: 11106027
    Abstract: A resolution enhancement technique for a line scanning confocal microscopy system that generates vertical and horizontal line scanning patterns onto a sample is disclosed. The line scanning confocal microscopy system is capable of producing line scanning patterns through the use of two alternative pathways that generate either the vertical line scanning pattern or horizontal line scanning pattern.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 31, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hari Shroff, Andrew York, John Giannini, Abhishek Kumar
  • Patent number: 11103572
    Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 31, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
  • Publication number: 20210260125
    Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Steven A. Feldman
  • Patent number: 11096927
    Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 24, 2021
    Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
  • Patent number: 11098283
    Abstract: Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjivan Gautam, Yun Ji, Luca Gattinoni
  • Patent number: 11098084
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Patent number: 11091509
    Abstract: The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, and L1 are defined in the disclosure. These linked purine pterin inhibitors bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing the HPPK inhibitors and methods of treating a bacterial infection in a patient with one or more of the HPPK inhibitors of the disclosure are also provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: August 17, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xinhua Ji, Genbin Shi, Gary X. Shaw
  • Publication number: 20210246494
    Abstract: The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 12, 2021
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20210246137
    Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.
    Type: Application
    Filed: April 22, 2021
    Publication date: August 12, 2021
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Loyola University of Chicago
    Inventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
  • Publication number: 20210246442
    Abstract: The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: August 12, 2021
    Applicant: The United States of America as represented by the Secretary, Department of Health & Human Services
    Inventors: Juan Rivera, Nicolas Charles
  • Patent number: 11084850
    Abstract: The present invention provides immunogens comprising a recombinant Respiratory Syncytial Virus (RSV) F protein stabilized in a prefusion conformation and nucleic acids encoding such immunogens. In particular the present invention provides polypeptides, polynucleotides, compositions, and uses thereof for eliciting an immune response to bovine respiratory syncytial virus (bRSV). Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: August 10, 2021
    Assignees: THE PIRBRIGHT INSTITUTE, INSTITUTE FOR RESEARCH IN BIO-MEDICINE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Lei Chen, Baoshan Zhang, Peter D. Kwong, Davide Corti, Antonio Lanzavecchia, Geraldine Taylor
  • Patent number: 11077178
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 3, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Liyanage Parakrama Perera, Thomas Alexander Waldmann, Kevin Charles Conlon, Pin-Yu Perera
  • Patent number: 11078286
    Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 3, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu, Tai Chi Cheuk